Sun Pharmaceutical Industries' quarterly net profit fell 36.2% to Rs 1,989 crore, largely due to one-time legal settlements and acquisition-related expenses. Despite these charges, the company’s core business grew, with revenue rising 11.9% to Rs 16,198.7 crore. Investors will likely focus on how these integration costs impact future cash flows and the progress of the Organon & Co acquisition.
Sun Pharmaceutical Industries reported a significant decline in its net profit for the quarter ending September 2026. While the company saw a healthy rise in total sales, the bottom line contracted by 36.2% year-on-year to Rs 1,989 crore. This drop was primarily driven by heavy one-time costs linked to legal settlements and the expenses of acquiring new businesses.
The most significant financial impact came from a settlement regarding the Generic Pharmaceuticals Pricing Antitrust Litigation in the United States. The company incurred a cost of Rs 922.67 crore to resolve this matter, which was only partially offset by a tax benefit of Rs 95.34 crore. Additionally, Sun Pharma spent Rs 346.16 crore on legal, filing, and advisory fees associated with its planned acquisition of Organon & Co. Management has indicated that further costs related to this acquisition may occur as the deal moves forward.
Operational Resilience and Core Growth
Despite the pressure from these one-off charges, the underlying business operations remained resilient. The company’s consolidated revenue grew by 11.9% to Rs 16,198.7 crore. Operating profit, measured as EBITDA, increased by 4.8% to Rs 4,743.9 crore, with an EBITDA margin of 29.3%. When excluding the impact of these exceptional legal and acquisition-related costs, the adjusted net profit actually rose by 1.4% to Rs 3,162 crore, suggesting that the core business continues to perform steadily.
A key driver of this growth is the global innovative medicines segment, which generated $356 million in sales during the quarter. This segment now accounts for roughly one-fifth of the company’s total revenue mix, indicating a successful pivot toward higher-value products. Furthermore, the company continued its focus on long-term growth by investing Rs 778.4 crore in research and development, which represents 4.8% of its total sales.
For shareholders and market watchers, the key monitorables moving forward will be the final integration process of the Organon & Co acquisition and any further developments in the U.S. legal environment. The company’s ability to manage these ongoing costs while maintaining margins in its innovative medicines segment will be critical to assessing future performance.